AMES, IA -- (Marketwired) -- 12/05/13 -- In the news release, " NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference," issued earlier today by NewLink Genetics Corporation (NASDAQ: NLNK), we are advised by the company that the conference date in the first paragraph
AMES, Iowa , May 17, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that abstracts from two clinical studies of its IDO pathway inhibitors, indoximod and navoximod (GDC-0919), used in combination with other agents, are now available on the website of the 2017
AMES, Iowa , May 18, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that an abstract describing data from a clinical study of its IDO pathway inhibitor, indoximod, in combination with chemotherapeutic agents for patients with newly diagnosed acute myelogenous
Algenpantucel-L Immunotherapy Phase 2 Data Featured in Plenary Session at 53rd Annual Meeting of the Society for Surgery of the Alimentary Tract and Will be Published in the Journal of Gastrointestinal Surgery
AMES, IA -- (Marketwired) -- 09/04/14 -- NewLink Genetics Corporation (NASDAQ: NLNK) today announced that the United States Food and Drug Administration (FDA) has given permission for the Company to proceed to Phase 1 clinical trials with their Ebola vaccine candidate.